Date: 2013-08-07
Type of information: Licensing agreement
Compound: GS Xceed™ Gene Expression System
Company: Lonza (Switzerland) Sorrento Therapeutics (USA)
Therapeutic area: Technology - Services - Cancer - Oncology - Inflammatory diseases - Infectious diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On August 7, 2013, Sorrento Therapeutics and Lonza have announced the signing of a non-exclusive research license agreement, for access to Lonza’s GS Xceed™ Gene Expression System. The GS Xceed™ System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio. The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed™ System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento’s lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.
Financial terms:
Latest news:
